https://www.fiercebiotech.com/biotech/regenxbio-gets-fda-support-hunter-syndrome-gene-therapys-accelerated-review-filing-2024
RegenXBio is sounding the alarms now that the Hunter Syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA.
gene therapyregenxbiogetsfdasupport
https://www.americanbankingnews.com/2025/11/27/regenxbio-nasdaqrgnx-trading-up-10-7-after-analyst-upgrade.html
Read REGENXBIO (NASDAQ:RGNX) Trading Up 10.7% After Analyst Upgrade at American Market News
regenxbionasdaqtradinganalystupgrade
https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37077499/gene-therapy-player-regenxbios-rgx-121-marks-success-in-trial-yet-faces-challenges-
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta...
gene therapyplayerregenxbiorgxmarks
https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-pivotal-enrollment-and-initiates-commercial-production-in-duchenne-gene-therapy-program-302599520.html
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II...
commercial productionregenxbioannouncescompletionpivotal
https://www.clinicaltrialsarena.com/news/fda-puts-regenxbio-gene-therapy-trials-on-hold-after-brain-tumour/
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
gene therapyfdaputsregenxbiotrials